ADMA BIOLOGICS, INC. (ADMA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | 121,984 | 114,802 | 119,839 | 107,191 |
| Cost of product revenue | 54,757 | 53,705 | 60,180 | 49,738 |
| Gross profit | 67,227 | 61,097 | 59,659 | 57,453 |
| Selling, general and administrative | 22,214 | 24,079 | 18,560 | 16,608 |
| Research and development | 1,031 | 826 | 412 | 560 |
| Plasma center operating expenses | 1,152 | 1,286 | 1,021 | 942 |
| Amortization of intangible assets | 32 | 25 | 28 | 142 |
| Total operating expenses | 24,429 | 26,216 | 20,021 | 18,252 |
| Income from operations | 42,798 | 34,881 | 39,638 | 39,201 |
| Other expense | -108 | -64 | -56 | -16 |
| Interest income | 400 | 608 | 666 | 449 |
| Interest expense | 1,834 | 1,975 | 3,499 | 3,783 |
| Loss on extinguishment of debt | -1,159 | - | - | - |
| Other expense, net | -2,701 | -1,431 | -2,889 | -3,350 |
| Income before income taxes | 40,097 | 33,450 | 36,749 | 35,851 |
| Provision for income taxes | 5,878 | 6,546 | 840 | 3,789 |
| Net income | 34,219 | 26,904 | 35,909 | 32,062 |
| Basic (in shares) | 241,490,715 | 237,775,476 | 234,571,376 | 232,417,645 |
| Basic earnings per common share (in dollars per share) | 0.14 | 0.11 | 0.15 | 0.14 |
| Diluted (in shares) | 248,608,460 | 244,676,350 | 244,804,065 | 242,167,072 |
| Diluted earnings per common share (in dollars per share) | 0.14 | 0.11 | 0.15 | 0.13 |